Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Pulmonary Embolism I: Introduction01:29

Pulmonary Embolism I: Introduction

Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
Pulmonary Embolism I: Introduction01:19

Pulmonary Embolism I: Introduction

A blood clot, or thrombus, is a semi-solid mass composed of fibrin, platelets, and red blood cells. When it forms within a vessel, it can obstruct blood flow, known as thrombosis. If part of the clot detaches, it becomes an embolus that can travel and block distant vessels. When this occurs in the pulmonary arteries, it causes a condition known as pulmonary embolism (PE).Origin and ImpactMost often, the embolus originates from a thrombus in the deep veins of the lower limbs, a condition called...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early Dynamics of Body Temperature in Acute Stroke: Insights into Outcomes and Management.

Journal of clinical medicine·2026
Same author

Early vs Delayed Extubation After Thrombectomy for Acute Ischemic Stroke: The EDESTROKE Randomized Clinical Trial.

JAMA neurology·2026
Same author

Measuring Accuracy (Classification Probabilities, Positive, and Negative Predictive Values) of Executive Function Electroencephalogram Metrics in Attention-Deficit/Hyperactivity Disorder Diagnosis: Protocol for and Perspectives From the SINCRONIA Study.

JMIR research protocols·2026
Same author

Linking first-pass reperfusion success to proteomic markers in large and medium vessel ischemic stroke: an exploratory study.

Precision clinical medicine·2026
Same author

In Vitro Analysis of TWEAK/Fn14 Axis in the Blood-Brain Barrier Models during Oxygen-Glucose Deprivation and Reoxygenation.

Molecular neurobiology·2026
Same author

Navigated and robotic-assisted sacroiliac joint fusion: a narrative review.

Expert review of medical devices·2026

Related Experiment Video

Updated: Jun 21, 2026

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis
08:50

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis

Published on: January 9, 2026

[Atherothrombosis: an excessively globalizing concept?].

José Castillo1, Miguel Blanco

  • 1Hospital Clínico Universitario, Universidad de Santiago de Compostela, La Coruña, España. jose.castilo@usc.es

Medicina Clinica
|July 28, 2009
PubMed
Summary

Clinical trials and registries like REACH advance vascular disease knowledge. Recognizing atherothrombosis is not the sole cause improves diagnosis and treatment efficacy for complex vascular conditions.

Area of Science:

  • Vascular medicine and epidemiology.
  • Cardiovascular research methodologies.

Context:

  • Clinical trials and prospective observational registries are key for understanding vascular disease.
  • Clinical trial generalizability is limited, particularly for multifactorial conditions like vascular disease.
  • The REACH registry offers extensive data on vascular diseases, overcoming many trial limitations.

Purpose:

  • To highlight the limitations of traditional clinical trials in complex diseases.
  • To emphasize the value of large-scale registries like REACH for vascular disease research.
  • To advocate for a broader understanding of vascular disease mechanisms beyond atherothrombosis.

Summary:

  • The REACH registry provides a comprehensive dataset for vascular disease research.
  • Limitations exist in generalizing clinical trial findings for multifactorial vascular diseases.

More Related Videos

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
09:19

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

Related Experiment Videos

Last Updated: Jun 21, 2026

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis
08:50

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis

Published on: January 9, 2026

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
09:19

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

  • Atherothrombosis is a significant mechanism, but not the only one, in vascular disease.

    • Impact:

    • Improved diagnostic accuracy for diverse vascular conditions.
    • Enhanced therapeutic strategies through a more complete understanding of disease mechanisms.
    • Advancement of epidemiological and clinical research in vascular medicine.